醋酸甲地孕酮治療子宮內(nèi)膜癌的臨床效果

　　[摘要]目的 探討醋酸甲地孕酮治療子宮內(nèi)膜癌的臨床效果。方法 選擇2016年7月～2017年7月我院收治的80例子宮內(nèi)膜癌患者，遵循患者的個(gè)人意愿進(jìn)行分組治療。其中，39例患者選擇常規(guī)治療，設(shè)為對(duì)照組，另外41例子宮內(nèi)膜癌患者設(shè)為觀察組，選擇在對(duì)照組的基礎(chǔ)上應(yīng)用醋酸甲地孕酮強(qiáng)化治療。對(duì)比兩組患者的治療效果以及生活質(zhì)量改善情況。結(jié)果 經(jīng)過(guò)治療后，兩組子宮內(nèi)膜癌患者均出現(xiàn)不同程度的胃腸道反應(yīng)，觀察組患者的胃腸道反應(yīng)發(fā)生率為9.76%，顯著低于對(duì)照組的35.90%，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。觀察組患者的復(fù)發(fā)率為7.32%，對(duì)照組為30.77%，兩組比較，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。觀察組患者治療后的生活質(zhì)量各項(xiàng)評(píng)分均高于對(duì)照組（P<0.05）。結(jié)論 醋酸甲地孕酮在治療子宮內(nèi)膜癌患者中的臨床價(jià)值確切，不僅能夠減少患者的胃腸道反應(yīng)、復(fù)發(fā)率，還可以顯著提高子宮內(nèi)膜癌患者的生活質(zhì)量，在臨床上的應(yīng)用效果非常重要，值得進(jìn)一步探討研究。
　　[關(guān)鍵詞]醋酸甲地孕酮；子宮內(nèi)膜癌；臨床效果
　　[中圖分類號(hào)] R737.3 [文獻(xiàn)標(biāo)識(shí)碼] A [文章編號(hào)] 1674-4721（2018）2（b）-0083-03
　　Clinical effect of Megestrol Acetate in the treatment of endometrial carcinoma
　　WANG Jing
　　Department of Gynecology，AnshanTumor Hospital in Liaoning Province，Anshan 114000，China
　　[Abstract]Objective To investigate the clinical effect of Megestrol Acetate in the treatment of endometrial carcinoma.Methods From July 2016 to July 2017，80 patients with endometrial cancer in our hospital were treated.According to their personal will，they were grouped.Among them，39 patients were treated with routine therapy，and the rest 41 patients with endometrial carcinoma treated with Megestrol Acetate on the basis of the control group for intensification.Patients treated by routine therapy was classified into control group，and by intensified treatment was categorized into observation group.The therapeutic effect and improvement of quality of life between the two groups were compared.Results After treatment，patients with endometrial cancer in the two groups occurred with gastrointestinal reactions to some extent.The incidence of gastrointestinal reaction in the observation group was 9.76%，significantly lower than that in the control group accounting for 35.90% with a statistical difference（P<0.05）.The recurrence rate was 7.32% in the observation group and 30.77% in the control group，which was displayed statistical significance after comparison （P<0.05）.The scores of quality of life in the observation group were all higher than those in the control group （P<0.05）.Conclusion Application of Megestrol Acetatein the treatment of endometrial cancer obtains a definite clinical value.It not only reduces the patient′s gastrointestinal reaction and recurrence rate，but also markedly improve the quality of life in endometrial cancer patients，which plays a vital role in clinical practice and is worthy of further study and exploration.
　　[Key words]Megestrol Acetate；Endometrial carcinoma；Clinical effect
　　子宮內(nèi)膜癌是婦科較為常見(jiàn)的疾病，近年來(lái)發(fā)病率呈現(xiàn)上升趨勢(shì)，該疾病的發(fā)生率在婦科常見(jiàn)病中僅次于宮頸癌和乳腺癌，已經(jīng)嚴(yán)重危害到女性患者的身體健康和生活質(zhì)量[1]。大部分子宮內(nèi)膜癌患者經(jīng)確診后首先進(jìn)行手術(shù)治療，但是由于子宮內(nèi)膜癌晚期患者復(fù)發(fā)率較高，預(yù)后效果較差，因此需要給予放療、化療、激素治療作為輔助方法，以降低癌細(xì)胞的轉(zhuǎn)移和復(fù)發(fā)，對(duì)控制患者的病情，提高其生活質(zhì)量起到重要作用[2]。筆者以醋酸甲地孕酮進(jìn)行輔助治療，探究該治療方法對(duì)提高子宮內(nèi)膜癌患者的生活質(zhì)量的意義，旨在為以后的臨床研究提供參考依據(jù)，現(xiàn)報(bào)道如下。

相關(guān)熱詞搜索：醋酸 子宮內(nèi)膜 臨床 效果 治療